西藏藥業(600211.SH):公司靜態市盈率為123.62 遠高於行業水平
格隆匯 7 月 31日丨西藏藥業(600211.SH)公佈,公司股價於2020年7月29日、7月30日、7月31日連續三個交易日內日收盤價格漲幅偏離值累計超過20%。根據中證指數有限公司網站發佈的數據,截至2020年7月31日,公司靜態市盈率為123.62,滾動市盈率為104.31,公司所處醫藥製造業行業靜態市盈率為60.18,滾動市盈率61.29,公司上述市盈率指標遠高於行業水平。敬請廣大投資者注意二級市場交易風險,理性決策,審慎投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.